Why is Biogen Pharma falling/rising?

As of 30-Sep, Biogen Pharmachem Industries Ltd is experiencing a decline in its stock price, currently at 0.83, reflecting a decrease of 0.02 or 2.35%. The stock has underperformed its sector by 1.76% today and has been on a consecutive downward trend for the last two days, resulting in a total decline of 3.49%. Over the past week, the stock has fallen by 6.74%, and its year-to-date performance shows a significant drop of 29.66%. Despite declaring positive results in the last two quarters, including substantial growth in profit before tax and profit after tax, the company faces challenges with weak long-term fundamental strength, evidenced by a low return on equity of 2.43% and a poor EBIT to interest ratio of 1.19.
In the broader market context, Biogen's recent performance contrasts sharply with the Sensex, which has seen a slight increase of 0.57% over the past month. The stock's liquidity appears to be diminishing, with a notable drop in delivery volume by 54.63% compared to the five-day average, indicating reduced investor participation. Additionally, while the stock is trading at a discount compared to its peers, the overall negative sentiment surrounding its long-term fundamentals and the significant decline in profits over the past year contribute to its current downward trajectory.